articleThe LancetNov 4, 2011Closed access

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

BIBrian I. RiniBEBernard EscudierPTPiotr TomczakАДА. Д. КапринCSCezary Szczylik

Cleveland Clinic · Institut Gustave Roussy · +15 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,842
total citations
FWCI
143.51
Percentile
100%
References
32
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Axitinib
  • Sorafenib
  • Medicine
  • Renal cell carcinoma
  • Oncology
  • Internal medicine
  • Clinical trial
  • Urology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding